Purple biotech presents additional mechanism of action data for nt219 at american association of cancer research 2021 annual meeting

Tel aviv, israel, april 13, 2021 (globe newswire) -- purple biotech ltd. ("purple biotech" ", or the "company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional preclinical data supporting the mechanism of action of nt219, a dual inhibitor, novel small molecule that simultaneously targets irs1/2 and stat3, were presented in a poster entitled "adaptation of colorectal cancer cells to the brain microenvironment: the role of irs2," at the american association of cancer research (aacr) 2021 annual meeting. these data update and expand on the results previously reported by the company from its collaboration with professor ido wolf, head of the oncology division at tel aviv sourasky medical center.
PPBT Ratings Summary
PPBT Quant Ranking